Literature DB >> 9212228

Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z).

H M Oosterkamp1, L Scheiner, M C Stefanova, K O Lloyd, C L Finstad.   

Abstract

Mucins, including MUC-1, are generally considered to be products of epithelial tissues and of their tumors. To examine the possible expression of MUC-1 in other cell types, a panel of human epithelial and non-epithelial tumor cell lines was studied by reverse transcriptase polymerase chain reaction (RT-PCR), Northern blot analysis, immunocytology and radioimmunoprecipitation. Using the highly sensitive RT-PCR method, products corresponding to the non-repetitive 5' and 3' MUC-1 sequences were detected in all the cell lines examined. Amplified products lacking the tandem repeat region of MUC-1, including a new short form (designated MUC-1/Z) different from the previously reported MUC-1/Y protein, were also detected in most cell lines tested. Northern blot analysis, using a probe to the variable number tandem repeat (VNTR) region, confirmed the presence of MUC-1 mRNA in the astrocytoma, melanoma and neuroblastoma cell lines studied. MUC-1 protein was detected by immunocytology in these cell lines using monoclonal antibody (MAb) 139H2. Immunoprecipitation analysis with [3H]-glucosamine-labeled cell lysates and MAb 139H2 or an antibody to the cytoplasmic domain, CT-1, detected MUC-1 protein in 2 epithelial cell lines, an astrocytoma cell line (SK-MG-4) but not in the melanoma and neuroblastoma cell lines studied. Northern blot analysis using a probe to the 3' end of MUC-1 mRNA, confirmed the presence of MUC-1 mucin and also identified short products corresponding to the size of the short variant forms. Protein products corresponding to the MUC-1/Y and MUC-1/Z variant forms were not observed using either [3H]-glucosamine-labeled OVCAR-3 cells or [3H]-amino acid-labeled MCF-7 cells and either CT-1 antibody or MAb 232A1, detecting an epitope to the C-terminal region. Thus, depending on the sensitivity of the assay used, varying amounts of MUC-1 mRNA and protein could be detected in non-epithelial tumor cell lines. Although the amounts of MUC-1 in these cell lines are much lower than in carcinomas, it is possible that MUC-1 mucin serves a similar function in non-epithelial as in epithelial cells. The possible role of MUC-1/Y and MUC-1/Z variant forms in these cell lines is not understood.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212228     DOI: 10.1002/(sici)1097-0215(19970703)72:1<87::aid-ijc13>3.0.co;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas.

Authors:  Kepal N Patel; Ellie Maghami; Volkert B Wreesmann; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Bhuvanesh Singh
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

Review 2.  Cellular and molecular biology of airway mucins.

Authors:  Erik P Lillehoj; Kosuke Kato; Wenju Lu; Kwang C Kim
Journal:  Int Rev Cell Mol Biol       Date:  2013       Impact factor: 6.813

3.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

4.  Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state.

Authors:  Y Altschuler; C L Kinlough; P A Poland; J B Bruns; G Apodaca; O A Weisz; R P Hughey
Journal:  Mol Biol Cell       Date:  2000-03       Impact factor: 4.138

Review 5.  Role of mucins in the skin during benign and malignant conditions.

Authors:  Subhankar Chakraborty; Neelima Bonthu; Benjamin J Swanson; Surinder K Batra
Journal:  Cancer Lett       Date:  2010-12-13       Impact factor: 8.679

6.  Comparison of proteolytic, cytotoxic and anticoagulant properties of chromatographically fractionated bromelain to un-fractionated bromelain.

Authors:  Samina Badar; Mohamed Azarkan; Ahmed H Mekkawy; Javed Akhter; Krishna Pillai; Rachida El Mahyaoui; Kevin Ke; Lauren Cavanaugh; David L Morris
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

7.  Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues.

Authors:  Subrata K Ghosh; Pamela Pantazopoulos; Zdravka Medarova; Anna Moore
Journal:  Clin Breast Cancer       Date:  2012-11-01       Impact factor: 3.225

8.  Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms.

Authors:  Lixin Zhang; Anda Vlad; Christine Milcarek; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2012-09-02       Impact factor: 6.968

Review 9.  MUC1: a multifaceted oncoprotein with a key role in cancer progression.

Authors:  Sritama Nath; Pinku Mukherjee
Journal:  Trends Mol Med       Date:  2014-03-22       Impact factor: 11.951

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.